{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Psychosis&page=2", "query": { "condition": "Acute Psychosis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Psychosis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T19:46:20.742Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04624243", "title": "Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo to MK-8189", "type": "DRUG" }, { "name": "Placebo to risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 499, "start_date": "2020-12-15", "completion_date": "2024-06-21", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 35, "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624243" }, { "nct_id": "NCT03055338", "title": "An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia, Acute Episode" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo matching MK-8189", "type": "DRUG" }, { "name": "Placebo matching risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 224, "start_date": "2017-03-08", "completion_date": "2018-01-09", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03055338" }, { "nct_id": "NCT07734493", "title": "A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "LTX-001 once daily", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LTX-001 twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leal Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 90, "start_date": "2026-08-03", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Los Alamitos, California • DeLand, Florida + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Alamitos", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07734493" }, { "nct_id": "NCT05227690", "title": "A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Emraclidine 10 mg", "type": "DRUG" }, { "name": "Emraclidine 30 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 385, "start_date": "2022-06-30", "completion_date": "2024-08-26", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 21, "location_summary": "Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Montclair", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05227690" }, { "nct_id": "NCT01400113", "title": "Treating Acutely Agitated Patients With Asenapine Sublingual Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Agitation" ], "interventions": [ { "name": "Asenapine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Unity Health Toronto", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 120, "start_date": "2012-04", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-05-16", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 1, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400113" }, { "nct_id": "NCT00080327", "title": "Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 370, "start_date": "2003-11", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2013-11-11", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 1, "location_summary": "Wallingford, Connecticut", "locations": [ { "city": "Wallingford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080327" }, { "nct_id": "NCT01234779", "title": "A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "bitopertin [RO4917838]", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 301, "start_date": "2011-02", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Pico Rivera", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234779" }, { "nct_id": "NCT04512066", "title": "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia, Schizoaffective Disorder" ], "interventions": [ { "name": "RO6889450", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 287, "start_date": "2020-09-08", "completion_date": "2022-06-21", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04512066" }, { "nct_id": "NCT01312272", "title": "Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Oxytocin", "type": "DRUG" }, { "name": "Inactive placebo nasal spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Greater Los Angeles Healthcare System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 24, "start_date": "2011-04", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-05-02", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01312272" }, { "nct_id": "NCT00694707", "title": "Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Cariprazine", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 732, "start_date": "2008-06-30", "completion_date": "2009-08-31", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-09-29T19:46:20.742Z", "location_count": 18, "location_summary": "Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694707" } ] }